FDA Approves Polypill Widaplik for Hypertension
WEDNESDAY, June 11, 2025 -- The U.S. Food and Drug Administration has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.
The combination pill is the first and only FDA-approved triple combination medication for use as an initial therapy in patients who will likely need multiple drugs to achieve their ideal blood pressure numbers. The pill is available in a standard dose, as well as two low doses, and can be used in those initiating treatment.
The FDA approval is based on positive results from two international phase 3 trials that compared Widaplik to dual combinations of its component drugs as well as to placebo. The results of both trials indicated that Widaplik significantly improved blood pressure control compared with the comparators.
The most common adverse event reported in patients treated with Widaplik was symptomatic low blood pressure. Additionally, Widaplik is contraindicated in patients with anuria or known hypersensitivity to other sulfonamide-derived drugs. Widaplik is not to be coadministered with aliskiren in patients with diabetes, and a boxed warning indicates discontinuation of Widaplik during pregnancy.
"I am very excited and pleased to have Widaplik approved for the treatment of hypertension in the U.S. Single-pill combination antihypertensive therapy has great potential to improve hypertension control in the U.S. and worldwide," Paul Whelton, M.D., of Tulane University in New Orleans and past president of the World Hypertension League, said in a statement. "Most patients with hypertension need multiple therapies to achieve their blood pressure goals. The new dose options available with Widaplik offer a treatment regimen that could benefit a broad range of patients, including those just starting treatment."
The approval of Widaplik was granted to George Medicines.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Implant Treats Blood Pressure Problems Among Spinal Injury Patients
THURSDAY, Sept. 25, 2025 — People with spinal cord injuries sometimes suffer from blood pressure problems, as their brain loses the ability to manage the body’s blood...
Three Health Conditions Raise Death Risk For Fatty Liver Disease
FRIDAY, Sept. 19, 2025 — People with fatty liver disease are more likely to die early if they have one of three additional health problems, a new study says. High blood...
Arthritis Drug, Methotrexate, Might Have Additional Heart-Healthy Benefit
TUESDAY, Sept. 9, 2025 — A common rheumatoid arthritis drug appears to also lower blood pressure, potentially reducing patients’ risk of heart disease, a new study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.